Unite with Fellow Investors
Choose the Best Attorney
Follow Case Progress
id: 267, Created by Stan Vick Chase, Scout
At 100 participants, legal proceedings can be initiated!
19 March 2018Class period Start
26 September 2018Class period End
16 February 2023Claim deadline
Julia Junge and Richard Junge v. Geron Corporation and John A. Scarlett.
" Lead Plaintiffs, on behalf of the Class, allege that Defendants violated Sections 10(b) and 20(a) of the Securities Exchange Act of 1934. Lead Plaintiffs allege that Defendants, along with Geron’s development partner, Janssen Biotech Inc. (“Janssen”), a division of Johnson & Johnson, were conducting a Phase 2 clinical trial called IMbark on Geron’s only drug candidate, imetelstat. It is alleged that during the Class Period, Defendants made materially false and misleading statements to investors, and failed to disclose material facts Defendants had a duty to disclose to make their representations not misleading, concerning certain study data results from the IMbark study and certain risk factors. The Complaint alleges that Defendants should have disclosed the allegedly bad news about the IMbark study data when they disclosed allegedly good news about the study. Allegedly, when the truth was disclosed at the end of the Class Period, Geron’s stock declined by over 71%."
Johnson Fistel, LLP
Kaplan Fox & Kilsheimer LLP
Northern District of California
Hon. William Alsup
$14000000 by cash, and $7000000 by Securities
+$24,000,000Total Settlement Amount